Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

LPA Group lowers FY guidance

(Sharecast News) - Electro-mechanical components engineering firm LPA Group reduced both revenue and earnings expectations on Friday due to lower sales at its recently acquired Martek Power business unit and the customer-led delayed delivery of an aerospace contract. For the year ending 30 September, LPA said group revenues were now expected to fall by roughly £3.0m to £21.5m, while adjusted pre-tax profits losses were seen at around £1.3m.

Reported pre-tax losses were anticipated to come in at £500,000, broadly in line with prior guidance. Order intake for the current year stood at approximately £27.0m,

Looking ahead, LPA said revenues were projected to ease by £1.5m to £27.0m in FY26. However, it also said it remained on track to deliver adjusted pre-tax profits of £600,000, underpinned by accelerated organisational restructuring initiatives.

LPA also announced the sale of freehold premises in Berkshire for £355,000, with cash proceeds earmarked to reduce net debt. Net book value was approximately £86,000 as at 31 March 2025.

The London-listed group said previous LPA operations at the premises have been relocated to other existing LPA sites, with the addition of a smaller leased office in the area.

The profit on disposal net of sale costs was expected to be recognised as exceptional income in the current year's results.

As of 1055 BST, LPA shares were down 3.33% at 43.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.